NCT04629729 2026-03-19FT819 in Subjects With B-cell MalignanciesFate TherapeuticsPhase 1 Active not recruiting54 enrolled
NCT03277729 2026-01-05A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasFred Hutchinson Cancer CenterPhase 1/2 Active not recruiting53 enrolled 11 charts
NCT03696784 2025-12-08Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell LymphomaUNC Lineberger Comprehensive Cancer CenterPhase 1 Active not recruiting19 enrolled
NCT02153580 2025-10-06Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaCity of Hope Medical CenterPhase 1 Active not recruiting37 enrolled
NCT04697940 2025-09-19Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHLChinese PLA General HospitalPhase 1/2 Active not recruiting33 enrolled